SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated robust cardiovascular and renal benefits in outpatient populations with type 2 diabetes, heart failure, and chronic kidney disease [7].